Dr. Postow on FDA Approval of Cemiplimab in Metastatic Cutaneous Squamous Cell Carcinoma

Partner | Cancer Centers | <b>Memorial Sloan Kettering Cancer Center </b>

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of cemiplimab in patients with advanced or metastatic cutaneous squamous cell carcinoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of cemiplimab in patients with advanced or metastatic cutaneous squamous cell carcinoma.